At Investor Conferences

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1816 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Calixar–SEVERAL: investment, 202003 second financing round €2.5m 2020-03-09
AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent 2020-03-04
BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform 2020-03-03
FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen 2020-02-25
Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund 2020-02-25
Scipio Bioscience–Financière Arbevel: investment, 202002 financing round Series A totalling €6m incl new + co-investor Financière Arbevel 2020-02-25
Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF 2020-02-25
Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures 2020-02-25
Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures 2020-02-25
Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere 2020-02-25
Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 2020-02-18
Apexbio/Cycloud–Stilla Technologies: digital PCR technology, 202002 distribution existent in China by Apexbio/Cycloud 2020-02-11
Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement 2020-02-11
Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners 2020-02-11
Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures 2020-02-11
Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners 2020-02-11
Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France 2020-02-11
Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds 2020-02-11
Stilla Technologies–SEVERAL: investment, 202002 financing round Series B €20m with new investor TUS-Holdings alongside existing investors 2020-02-11
Stilla Technologies–TUS-Holdings: investment, 202002 financing round Series B totalling €20m incl new investor CLIIF Investment Fund of Tuspark Europe 2020-02-11
MaaT Pharma–Biocodex: investment, 202002 financing round Series B totalling €18m incl existing investor Biocodex 2020-02-05
MaaT Pharma–BPCE: investment, 202002 financing round Series B totalling €18m incl existing investor Seventure Partners 2020-02-05
MaaT Pharma–Crédit Mutuel-CIC: investment, 202002 financing round Series B totalling €18m incl existing investor Crédit Mutuel Innovation 2020-02-05
MaaT Pharma–SEVERAL: investment, 202002 financing round Series B €18m with SymBiosis + Seventure + Crédit Mutuel Innovation + Biocodex et al. 2020-02-05
MaaT Pharma–SymBiosis LLC: investment, 202002 financing round Series B totalling €18m incl new investor SymBiosis LLC 2020-02-05
MaaT Pharma–Trophic Communications: public relations, 202002 service existent by Trophic Communications 2020-02-05
Inato–SEVERAL: investment, 202002 financing round Series A $14m led by Obious Ventures + Cathay Innovation 2020-02-04
Valneva–Deerfield: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed 2020-02-03
Valneva–OrbiMed: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed 2020-02-03
Valneva–SEVERAL: credit, 202002–202601 debt financing $60m + optional $25m facility from Deerfield Management + OrbiMed 2020-02-03
GeNeuro–Mérieux: investment, 202001 private placement totalling €17.5m incl €7.5m from existing investor GNEH SAS now largest shareholder with 36.46% 2020-01-31
GeNeuro–SEVERAL: investment, 202001 private placement €17.5m with 5.93m new shares at €2.95/share incl existent investor GNEH SAS 2020-01-31
Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies 2020-01-28
Stilla Technologies–Coulter Partners: recruitment services, 202001 supply service placement of Khaled Bahi as CFO at Stilla Technolgies 2020-01-28
PDC*line Pharma–SEVERAL: investment, 202001 financing round Series B €13.9m with existing + new investors 2020-01-22
Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA 2020-01-20
Seekyo–EU (govt): credit, 202001 EIF Investment Initiation Loan €150k 2020-01-20
Seekyo–France (govt): credit, 202001 convertible bond €250k financing from French Tech Seed Fund managed by Bpifrance 2020-01-20
Seekyo–SEVERAL: investment, 202001 seed financing round €400k from investors from three business angel networks 2020-01-20
Jeito Capital–SEVERAL: investment, 202001 closing €200m of Jeito I fund 2020-01-15
Urania Therapeutics–France (govt): credit, 202001 repayable advances €850k from Bpifrance 2020-01-14
Urania Therapeutics–France (govt): grant, 202001 subsidies €850k from Bpifrance 2020-01-14
Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters 2020-01-13
Domain Therapeutics–SEVERAL: credit, 202001 debt financing €6m fomr Bpifrance + BPALC + CIC + CEGEE 2020-01-13
Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications 2020-01-12
Alderaan Biotechnology–Advent France Biotechnology: investment, 202001 financing round Series A totalling €18.5m incl existing investor AFB 2020-01-09
Alderaan Biotechnology–Medicxi: investment, 202001 financing round Series A totalling €18.5m incl new investor Medicxi 2020-01-09
Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi 2020-01-09
Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform 2020-01-09
Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures 2020-01-08
Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund 2020-01-08
Eyevensys–CapDecisif: investment, 202001 financing round Series B totalling $30m incl existing + co-investor CapDecisif 2020-01-08
Eyevensys–France (govt): investment, 202001 financing round Series B totalling $30m incl existing + co-investors Bpifrance + Inserm Transfert 2020-01-08
Eyevensys–Pontifax: investment, 202001 financing round Series B totalling $30m incl existing + co-investor Pontifax 2020-01-08
Eyevensys–Quark Venture: investment, 202001 financing round Series B totalling $30m incl new + co-investor GHS Fund (Quark Venture + GF Securities) 2020-01-08
Eyevensys–RooneyPartners: public relations, 202001 service existent by RooneyPartners 2020-01-08
Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund 2020-01-08
Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve 2020-01-08
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis 2020-01-06
TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine 2020-01-01
Novartis–Voluntis: digital therapeutics, 201912–collab developm digital therapeutics using Theraxium Oncology platform for breast cancer 2019-12-18
Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB 2019-12-16
Voluntis–Salesforce: CRM software, 201912– collab using Salsesforce cloud + analytics s/w to implement VPS DTx prescription + reimbursement 2019-12-16
Aelis Farma–NewCap: public relations, 201912 service existent by NewCap 2019-12-13
Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA 2019-12-13
Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance 2019-12-13
Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group 2019-12-10
Synthorx–Sanofi: investment, 201912– acquisition $2.35b cash tender offer at $68/share ANNOUNCED 2019-12-09
ImCheck Therapeutics–Agent Capital: investment, 201912 financing round Series B totalling €48m incl new + co-investor Agent Capital 2019-12-04
ImCheck Therapeutics–Alexandria Real Estate: investment, 201912 financing round Series B totalling €48m incl new + co-investor Alexandria Venture 2019-12-04
ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF 2019-12-04
ImCheck Therapeutics–Dechert: legal services, 201912 supply service Dechert LLP acted as legal counsel for €48m Series B round of ImCheck 2019-12-04
ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck 2019-12-04
ImCheck Therapeutics–Eurazeo: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners 2019-12-04
ImCheck Therapeutics–France (govt): investment, 201912 financing round Series B totalling €48m incl co-lead investor Bpifrance InnoBio 2 + LV funds 2019-12-04
ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv 2019-12-04
ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners 2019-12-04
ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP 2019-12-04
ImCheck Therapeutics–Pfizer: investment, 201912 financing round Series B totalling €48m incl co-lead investor Pfizer Ventures 2019-12-04
ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures 2019-12-04
ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic 2019-12-04
ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners 2019-12-04
Diabeloop–SEVERAL: investment, 201912 financing round Series B €22m led by Cemag Invest 2019-12-02
Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials 2019-12-02
Sanofi–Ligand: transgenic animal technology, 201912– license ww for OmniAb platform 2019-12-02
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
Tissium–SEVERAL: investment, 201911 financing round Series B €38.75m from EIB + French investors 2019-11-20
Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m 2019-11-06
AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech 2019-11-06
Urania Therapeutics–Advent France Biotechnology: investment, 201911 seed financing round totalling €3.53m incl lead investor AFB 2019-11-06
Urania Therapeutics–Andrew Lloyd Associates: public relations, 201911 service existent by ALA 2019-11-06
Urania Therapeutics–Capital Grand Est: investment, 201911 seed financing round totalling €3.53m incl co-investor Cap Innov’Est 2019-11-06
Urania Therapeutics–Novalix: drug development services, 201911– supply of drug development services to Urania by Novalix 2019-11-06
Urania Therapeutics–SEVERAL: investment, 201911 seed financing round €3.53m led by Advent France Biotechnology + incl Cap Innov’Est 2019-11-06
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top